Furthermore, the pan-cancer STMN2.SIG exhibited enhanced predictive capabilities across the training, internal validation, and external validation datasets (Figure 9D), as well as in the aggregated datasets of different cancer types (Figure 9E). Here, STMN2 is linked to cancer.